MUVON Therapeutics is a Biotech Spin-off from the University of Zurich with the goal of developing and commercializing an autologous cell therapy for the regeneration of skeletal muscle tissue. Our initial area of focus is developing a safe and effective treatment for stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.
Together, we aim to establish personalized therapeutic solutions as the primary standard of care. Our goal is to offer the patients in need minimally invasive, low-risk treatments for the regeneration of skeletal muscle tissue, to help them regain control over their life.
MUVON Therapeutics is developing an autologous cell therapy for the treatment of diseases related to skeletal muscle damage or degradation. Our technology enables the targeted isolation of muscle precursor cells (MPCs) from muscle tissue, the controlled expansion of these cells and the regeneration of muscle tissue through injection of the expanded cells.